MET异常NSCLC的遗传异质性及其对免疫治疗结局的影响
该研究分析337例MET异常IIIB/IV期NSCLC标本,发现METamp与METex14分子特征不同;METamp中GCN≥10者OS显著更差,且METamp患者ICI治疗OS优于化疗,而METex14患者ICI与化疗无显著差异。
要点
- METamp肿瘤共突变频率高,METex14肿瘤57.6%无额外突变。
- METamp中GCN≥10者OS显著差于GCN<10者(4.0 vs 12.0个月)。
- METamp患者ICI治疗OS优于化疗,METex14患者两者无显著差异。
核心结论
- METex14、METamp GCN≥10和METamp GCN<10代表分子和临床特征不同的MET失调NSCLC亚组。
- METex14患者似乎不能从免疫治疗中获益,而METamp患者可获益,尤其预后差的METamp GCN≥10亚组。
研究设计与样本
- 回顾性分析337例MET异常IIIB/IV期NSCLC肿瘤标本,采用NGS、FISH和IHC检测。
- 评估MET异常类型、共突变、PD-L1表达和总生存期(OS)。
主要发现
- METamp肿瘤(n=278)各扩增级别共突变频率均>80%,METex14肿瘤(n=59)中57.6%无额外突变。
- METamp中随GCN增加,TP53失活突变频率升高(GCN<4:58.2%;GCN≥10:76.5%),KRAS突变频率降低(GCN<4:43.2%;GCN≥10:11.8%)。
- METamp中GCN≥10者OS为4.0个月(95%CI:1.9-6.0),显著差于GCN<10者的12.0个月(95%CI:9.4-14.6)。
- METamp患者ICI治疗OS为19.0个月(95%CI:15.8-22.2),优于化疗的8.0个月(95%CI:5.8-10.2,p<0.0001)。
- METex14患者ICI治疗与化疗的中位OS无显著差异(p=0.147)。
临床怎么用
- 对MET异常NSCLC应区分METex14与METamp,并报告METamp的GCN水平以指导预后判断。
- METamp患者可考虑ICI治疗,尤其GCN≥10亚组虽预后差但仍可能从ICI获益。
- METex14患者免疫治疗获益不显著,治疗选择需谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Robust data on the outcome of MET-aberrant NSCLC with nontargeted therapies are limited, especially in consideration of the heterogeneity of MET-amplified tumors (METamp). METHODS: A total of 337 tumor specimens of patients with MET-altered Union for International Cancer Control stage IIIB/IV NSCLC were analyzed using next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry. The evaluation focused on the type of MET aberration, co-occurring mutations, programmed death-ligand 1 expression, and overall survival (OS). RESULTS: METamp tumors (n = 278) had a high frequency of co-occurring mutations (>80% for all amplification levels), whereas 57.6% of the 59 patients with MET gene and exon 14 (METex14) tumors had no additional mutations. In the METamp tumors, with increasing gene copy number (GCN), the frequency of inactivating TP53 mutations increased (GCN < 4: 58.2%; GCN ≥ 10: 76.5%), whereas the frequency of KRAS mutations decreased (GCN < 4: 43.2%; GCN ≥ 10: 11.8%). A total of 10.1% of all the METamp tumors with a GCN ≥ 10 had a significant worse OS (4.0 mo; 95% CI: 1.9-6.0) compared with the tumors with GCN < 10 (12.0 mo; 95% confidence interval [CI]: 9.4-14.6). In the METamp NSCLC, OS with immune checkpoint inhibitor (ICI) therapy was significantly better compared with chemotherapy with 19.0 months (95% CI: 15.8-22.2) versus 8.0 months (95% CI: 5.8-10.2, p < 0.0001). No significant difference in median OS was found between ICI therapy and chemotherapy in the patients with METex14 (p = 0.147). CONCLUSIONS: METex14, METamp GCN ≥ 10, and METamp GCN < 10 represent the subgroups of MET-dysregulated NSCLC with distinct molecular and clinical features. The patients with METex14 do not seem to benefit from immunotherapy in contrast to the patients with METamp, which is of particular relevance for the prognostically poor METamp GCN ≥ 10 subgroup.
引用
- Kron A, Scheffler M, Heydt C, et al. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy. J Thorac Oncol. 2020. PMID: 33309988. doi:10.1016/j.jtho.2020.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。